Day 2 May 21 (Thu.) 2026

Plenary Session | Scientific Program | Educational Session | Free Papers(Oral) | Social Event

E English Session | Simultaneous Interpretation | Web Live Streaming Session

DAY 2

PACIFICO Yokohama Conference Center

Room 1	Main Hall (1F)	Web Symposium 12 ICAD and RNF213-Related Vasculopathy in East Asia E; Web PL-01 Plenary Lecture 01 Speaker : Josep Dalmau Chair : Takahiro Iizuka E; LS-15 Eisai Japan／Biogen Japan; Web Pr President Lecture Speaker : Kazutoshi Nishiyama Chair : Fumihiko Sakai; Web JSN Awards Ceremony; Web Japanese Society of Neurology 2025 Award Winner Lecture; Web 2026 Special Symposium 01 Envisioning the Future of the Japanese Society of Neurology
Room 2	301 (3F)	Symposium 13 ALS and lipid metabolism abnormalities: pathophysiological analysis for treatment strategies and iPS cell drug discovery; O-10 Motor neuron disease 2; LS-16 Novartis Pharma K.K.; Hot Topics 05 Cell Transplantation Therapy for Parkinson's Disease: Clinical Trajectory and Future Outlook E; ES-01 Eli Lilly Japan K.K. ／ Daiichi Sankyo Co., Ltd.
Room 3	302 (3F)	Web Symposium 14 The cutting edge strategies for management of breakthrough stroke; O-11 Cerebrovascular disease 2 E; LS-17 UCB Japan Co., Ltd.; Web Symposium 20 Principles and Practice of Preventive Neurology: a rapidly burgeoning field of Neurology E
Room 4	303 (3F)	Symposium 15 Migraine pathophysiology: An in-depth analysis; O-12 Parkinson's disease 2; Web LS-18 AbbVie GK; Symposium 21 Neurology meets Pharmacogenomics(PGx)
Room 5	304 (3F)	O-13 Clinical neurophysiology; LS-19 Alexion Pharma GK
Room 6	311+312 (3F)	O-14 Neuroradiology, Functional image E; LS-20 GlaxoSmithKline K.K.; ES-02 CHUGAI PHARMACEUTICAL CO., LTD.
Room 7	313+314 (3F)	LS-21 Medical Affairs, Lundbeck Japan K.K.; ES-03 ONO PHARMACEUTICAL CO., LTD.
Room 8	315 (3F)	Symposium 16 State-of-the-Art Insights into the Pathogenesis of Repeat-Associated Muscle Diseases; O-15 Dystonia/ Involuntary movement; LS-22 CHUGAI PHARMACEUTICAL CO., LTD.; Hot Topics 06 Clinical Neurorehabilitation: A quarter century of progress and future outlook; ES-04 Novartis Pharma K.K.
Room 9	414+415 (4F)	Hot Topics 04 Frontiers in the Treatment of Spinocerebellar Degeneration — From Rehabilitation to Clinical Trials; O-16 Cerebellar ataxia・Spastic paraplegia 2; LS-23 SCRUM Inc; Hot Topics 07 The Future of Gene Editing in Neurological Disease Therapy: From CRISPR to Japan-Originated Technologies at the Forefront of Research; ES-05 PDRadiopharma Inc. ／ The Japanese Council of Nuclear Neuroimaging ／ Japanese Society of Nuclear Medicine
Room 10	416+417 (4F)	Web Symposium 17 Do neurologic diseases start at the autonomic nerves? E; O-17 Parkinson's syndrome E; LS-24 FP Pharmaceutical Corporation; Web Symposium 22 How to access and treat gait disorders E; ES-06 Japan Blood Products Organization
Room 11	418 (4F)	Symposium 18 Advances in Inherited Peripheral Neuropathies: Latest Findings in Molecular, Clinical, and Pathological Research; O-18 Neurogenetics E; LS-25 Novo Nordisk Pharma Ltd.; Symposium 23 Exploring the pathomechanism of neurological diseases from the perspective of endoplasmic reticulum function -From basic science to human neuropathology -
Room 12	419 (4F)	Meet the Expert Meet the AAN President: Emerging Leadership in Neurology -Perspectives from Young and Female Physicians- E; O-19 Neuroinfection E; LS-26 Alnylam Japan K.K; LB Late Breaking Symposium E
Room 13	501 (5F)	LM-03 Lecture Marathon 03; LM-04 Lecture Marathon 04; O-20 Neuroimmunology 2 (MS・NMO); LS-27 Eli Lilly Japan K.K.; LM-05 Lecture Marathon 05; LM-06 Lecture Marathon 06; ES-07 Eisai Co., Ltd.
Room 14	502 (5F)	New Guideline 02 Clinical practice guidelines for HTLV-1-associated myelopathy 2025; O-21 Dementia and related pathologies; LS-28 argenx Japan K.K; Symposium 24 Advances in Imaging Biomarkers in Multiple Sclerosis; ES-08 Medical Affairs Division, Johnson & Johnson
Room 15	503 (5F)	Symposium 19 Understanding pathogenesis for therapeutic strategy of MG in the future; O-22 Neuromuscular junction disease; LS-29 Tanabe Pharma Corporation; Symposium 25 Considering the co-pathogeneses in neurodegenerative diseases
PACIFICO Yokohama Exhibition Hall	Poster Session / Exhibition	Hall B (1F) — Poster Preparation / Poster Viewing; Poster Viewing; Poster Presentation / Discussion; Poster Removal; Exhibition

7:00 8:00 9:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00